{"id":"igpro10","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IgPro10","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:48:42.829850+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T04:48:57.710193+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:48:48.335196+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IgPro10","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:48:48.657596+00:00"}},"_dailymed":null,"aiSummary":"IgPro10, marketed by CSL Behring, is an immunoglobulin product with a well-established presence in the market. The key composition patent for IgPro10 is set to expire in 2028, providing a significant period of exclusivity and competitive advantage. The primary risk to IgPro10 is the potential increase in competition following the patent expiry in 2028.","_scrapedAt":"2026-03-27T23:48:09.745Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:48:57.710268+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT03684018","phase":"PHASE4","title":"Two Dose Levels of Privigen in Pediatric CIDP","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2019-02-28","conditions":"Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","enrollment":30},{"nctId":"NCT01184846","phase":"PHASE3","title":"Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2010-11","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":31},{"nctId":"NCT04137224","phase":"PHASE2","title":"Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2019-09-19","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":27},{"nctId":"NCT04138485","phase":"PHASE2","title":"Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)","status":"WITHDRAWN","sponsor":"CSL Behring","startDate":"2019-12-20","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":""},{"nctId":"NCT01545076","phase":"PHASE3","title":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-03","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy","enrollment":208},{"nctId":"NCT01390649","phase":"PHASE4","title":"A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-11","conditions":"Immune Thrombocytopenic Purpura","enrollment":57},{"nctId":"NCT00322556","phase":"PHASE3","title":"Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2005-11","conditions":"Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency","enrollment":55},{"nctId":"NCT00168025","phase":"PHASE3","title":"Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2004-09","conditions":"Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency","enrollment":89},{"nctId":"NCT00168038","phase":"PHASE3","title":"Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2004-12","conditions":"Immune Thrombocytopenic Purpura","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Human normal immunoglobulin","Privigen"],"phase":"marketed","status":"active","brandName":"IgPro10","genericName":"IgPro10","companyName":"CSL Behring","companyId":"csl-behring","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:48:57.710268+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}